Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

ImmunityBio (NASDAQ:IBRX) Stock Surges 10% as Record Anktiva Sales and a January 6 FDA Decision Date Draw Buyers

ImmunityBio (NASDAQ:IBRX), the San Diego commercial-stage immunotherapy company whose lead product Anktiva is an IL-15 superagonist approved with BCG for a form of bladder cancer, is surging in Friday's session. The shares are up 9.55% at $10.17 on volume more than double the average …

Nitish Kishor | 02 October 2026

Kodiak Sciences (NASDAQ:KOD) Stock Drops 9% as Profit-Taking and Dilution Worries Follow a Historic Phase 3 Rally

Kodiak Sciences (NASDAQ:KOD), the Palo Alto, California biopharmaceutical company developing treatments for chronic retinal diseases, is falling in Friday's session. The shares are down 8.74% at $89.86, giving back part of a rally in which the stock rose 178% on September 28 and reached …

Nitish Kishor | 02 October 2026

Nanobiotix (NASDAQ:NBTX) Stock Extends Slide, Down 8%, After a CFO Change Ahead of the Pivotal NANORAY-312 Readout

Nanobiotix (NASDAQ:NBTX), the Paris-based late-stage biotechnology company developing physics-based cancer treatments, is falling again in Friday's session. The shares are down 7.54% at $25.80, extending a slide of about 10.5% in the prior session, when the Paris listing fell about 8%.

Nitish Kishor | 02 October 2026

Oscar Health (NYSE:OSCR) Stock Rebounds 3% on Higher 2026 Operating Earnings Guidance After Its Investor Day

Oscar Health (NYSE:OSCR), the New York-based health insurer that sells Affordable Care Act andMedicareAdvantage plans to more than 3 million members through its own technology platform, is rebounding in Friday's session. The shares are up 3.48% at $30.94 after a roughly 3% drop in …

Nitish Kishor | 02 October 2026

PACS Group (NYSE:PACS) Stock Rebounds 4% as 17 of Its Nursing Homes Make a National Best Nursing Homes List for 2027

PACS Group (NYSE:PACS), the Salt Lake CityHolding Companywhose subsidiaries run 355 post-acute facilities across 20 states and serve more than 33,400 patients daily, is rebounding in Friday's session. The shares are up 3.83% at $42.60 on lighter-than-average volume, while the healthcare sector is little …

Nitish Kishor | 02 October 2026

Qiagen (NYSE:QGEN) Stock Jumps 7% on a Report That Talks With a Strategic Buyer Have Advanced

Qiagen (NYSE:QGEN), the Venlo, Netherlands provider of sample preparation and molecular testing tools for life sciences and diagnostics customers, is jumping in Friday's session on a report that talks with a strategic buyer have advanced. The shares are up 6.85% at $44.92 on above-average …

Nitish Kishor | 02 October 2026

Addex Therapeutics (NASDAQ:ADXN) Penny Stock Slips 3% Pre-Market: Executive Changes Land After a Sharp Rally

Addex Therapeutics (NASDAQ:ADXN), a penny stock from a Geneva-based clinical-stage company developing small-molecule allosteric modulators for neurological disorders, is slipping in pre-market trading after announcing executive changes. Shares are at $2.88, down 3.30% from Thursday's close of $2.98, which itself followed a 7.97% gain.

Nitish Kishor | 02 October 2026

AngioDynamics (NASDAQ:ANGO) Edges Up Pre-Market: Pulmonary Embolism Research Award Is a Modest Catalyst

AngioDynamics (NASDAQ:ANGO), a Latham, New York medical technology company focused on vascular disease and cancer treatment, is edging higher in pre-market trading. Shares are at $15.40, up 1.85% from Thursday's close of $15.12, slightly ahead of a healthcare sector fund up about 0.4%.

Nitish Kishor | 02 October 2026

Artiva Biotherapeutics (NASDAQ:ARTV) Gains 5% Pre-Market: Updated Sjögren Disease Data Draws Buyers After a Rough Session

Artiva Biotherapeutics (NASDAQ:ARTV), a San Diego clinical-stage company developing off-the-shelf natural killer cell therapies for autoimmune diseases, is rebounding in pre-market trading after closing Thursday at $6.79. Shares are at $7.14, up 5.15%, with no new announcement identified for Friday.

Nitish Kishor | 02 October 2026

BioCardia (NASDAQ:BCDA) Advances Helix Catheter Toward FDA Clearance With Revised Submission

BioCardia Inc (NASDAQ:BCDA), a company focused on cellular and cell derived therapeutics for cardiovascular and pulmonary disease, announced it has completed a revised De Novo pre-submission to the FDA's Center for Devices and Radiological Health for its Helix catheter. The device is designed to …

Nitish Kishor | 02 October 2026
Support

Hi! How can we help you today?

Loading…